| 產品名稱 |
YI 328-18 |
| 商品貨號 |
B165988 |
| Organism |
Mus musculus (B cell); Mus musculus (myeloma), mouse (B cell); mouse (myeloma) |
| Product Format |
frozen |
| Morphology |
lymphoblast |
| Culture Properties |
suspension |
| Biosafety Level |
1
Biosafety classification is based on U.S. Public Health Service Guidelines, it is the responsibility of the customer to ensure that their facilities comply with biosafety regulations for their own country. |
| Strain |
Strain: ?BALB/c? (B cell); BALB/c (myeloma) |
| Applications |
Both YI328-18 (ATCC HB-9306)and YI328-51 (ATCC HB-9307) specifically recognize the abnormal branching structure of the lactoganglioseries glycolipid antigen molecule and have
almost no cross-reactivity with smaller unbranched segments. |
| Disclosure |
This material is cited in a US or other Patent and may not be used to
infringe the claims. Depending on the wishes of the Depositor, ATCC may be
required to inform the Patent Depositor of the party to which the material was
furnished. This material may not have been produced or characterized by ATCC. |
| Derivation |
Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells. |
| Genes Expressed |
immunoglobulin; monoclonal antibody; against glycosphingolipid |
| Cellular Products |
immunoglobulin; monoclonal antibody; against glycosphingolipid |
| Comments |
Animals were immunized with a synthetic lactoganglioseries glycolipid. Spleen cells were fused with P3X63Ag8U.1 mouse myeloma cells. Both YI328-18 (ATCC HB-9306)and YI328-51 (ATCC HB-9307) specifically recognize the abnormal branching structure of the lactoganglioseries glycolipid antigen molecule and have
almost no cross-reactivity with smaller unbranched segments. |
| Complete Growth Medium |
The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, ATCC 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum (ATCC 30-2020) to a final concentration of 10%.
|
| Subculturing |
Medium Renewal: Every 2 days Cultures can be maintained by the addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation with subsequent resuspension at 1 to 2 X 10 exp5 viable cells/ml. Maintain cell density between 1 X 10 exp5 and 1 X 10 exp6 viable cells/ml. |
| Cryopreservation |
Freeze medium: complete growth medium supplemented with an additional 10% fetal bovine serum and 10% (v/v) DMSO. |
| Culture Conditions |
Temperature: 37.0°C |
| Isotype |
IgG3 |
| Name of Depositor |
R Kannagi |
| U.S. Patent Number |
|
| References |
Kannagi R, et al. Monoclonal antibodies specific for synthetic glycosphingolipids having abnormal branched structure. US Patent 4,885,358 dated Dec 5 1989
|
